SS
SYRS

SBI Securities’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

SBI Securities’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,883
Closed -$433 – 4231
2024
Q4 		$433 Buy
+1,883
New +$2.26K ﹤0.01% 2946

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SBI Securities's SYRS Position: Q1 2025 in Review

SBI Securities sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 1,883 shares — an estimated $433 sold.

SBI Securities first reported a position in SYRS in Q4 2024 and held it in 1 quarter. The position peaked at $433 in Q4 2024. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • SBI Securities reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • SBI Securities sold 1,883 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $433.
  • SBI Securities first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
  • SBI Securities's Syros Pharmaceuticals, Inc. Common Stock position peaked at $433 in Q4 2024.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on SBI Securities's 13F filing for Q1 2025, filed 2 May 2025.